Paperonium

Lung cancer · Nat Commun · 2025

The paper’s summary: half of 63 patients lived 11.1 months without cancer growing. Its data: 5.5.

Rival drug, spot A, its own trial: 12.0The summary: spot A, 63 patients11.1 monthsIts results and data file: same 635.5 monthsSpot B, 19 patients: all sources agree3.5 months024681012
Rival drug, spot A, its own trial: 12.0The summary:spot A, 63 patients11.1 monthsIts results and datafile: same 635.5 monthsSpot B, 19 patients:all sources agree3.5 months024681012

Months until half the patients’ cancer had grown or they had died

The paper says

Lung-cancer pill trial: each cancer had extra DNA in one gene, at spot A or B. Does the spot matter? For 63 spot-A patients, the summary at the top of the paper says half lived 11.1 months without cancer growing; for 19 spot-B patients, 3.5.

Its own data show

The paper’s detailed results section gives 5.5 months for the same 63 patients, and redoing the calculation from its patient-by-patient file gives 5.5 too. That file labels 42 of the 63 “grew or died” and 21 “not yet”. Flip those two labels and the file gives the summary’s 11.1, the only change found that does.

“Not yet” means alive with no growth seen at the last check-up; such patients count as lasting at least that long. Flip the labels and 21 count as grown or died, not 42, so 5.5 becomes 11.1: near a rival drug’s 12.0 months, which the summary sets beside it. The 5.5 is under half that, yet beats spot B’s 3.5.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity · Nat Commun (2025) · doi:10.1038/s41467-025-61817-8